SESerdar Epçaçan

Serdar Epçaçan

*This is an algorithmically generated author record based on publicly available information.

Serdar Epçaçan has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ischemia-modified albumin may not be a Reliable Biomarker in Children with Acute Rheumatic Fever

    by Yasemin Dönmez, Mehmet Gökhan Ramoğlu, Zerrin Karakuş Epçaçan, Mustafa Orhan Bulut, Serdar Epçaçan

    Aim: Acute rheumatic fever (ARF) poses significant health challenges in developing regions, particularly due to its potential to cause severe cardiac complications. This study investigates the role of ischemia-modified albumin (IMA) as a biomarker for inflammation in children diagnosed with ARF in a moderate altitude area. Methods: Conducted between January 2019 and May 2020 at a regional hospital located at the moderate altitude, the study included 25 ARF patients and a control group of 25 healthy children. Clinical assessments and echocardiographic evaluations were performed, alongside serum IMA level measurements at diagnosis and post-treatment. Results: indicated that while acute phase reactants such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were elevated in ARF patients, IMA levels were not significantly different from those in the control group, both at diagnosis and after treatment. Specifically, IMA levels were lower at diagnosis (0.62 ± 0.73 ng/ml) compared to post-treatment (1.18 ± 0.94 ng/ml), with no consistent correlation to CRP, although a negative correlation with ESR was observed. Conclusion: These findings suggest that IMA may not be a reliable biomarker for diagnosing and monitoring ARF in children in moderate region, challenging previous claims about its utility in patients with acute rheumatic fever. Further research is warranted to explore the effects of altitude and other environmental factors on IMA levels in this population.

  • Behavioural interventions to increase adherence to palivizumab prophylaxis in children with CHD

    by Elif Erolu, Özgür Kıbrıs, Yasemin Tosun, Ayse Yildirim, Ozge Pamukcu, Evic Zeynep Basar, Kadir Babaoglu, Serdar Epcacan, Yasemin Donmez, Dilek Giray, et al.

    Objectives: Adherence to palivizumab prophylaxis programmes is crucial to protect infants with CHD against respiratory syncytial virus infections. We analysed the effectiveness of two nudge interventions in increasing adherence.Methods: Our study included 229 infants, and their caregivers, from five centers in Turkey in the 2020–2021 respiratory syncytial virus season. We randomly allocated caregivers to a control and two intervention groups. Caregivers in all groups were informed about the prophylaxis programme and provided a schedule. Additionally, caregivers in Intervention 1 were called two days before appointments (default bias) and were asked to plan the appointment day (implementation intention), whereas caregivers in Intervention 2 received biweekly text messages informing them about the programme’s benefits (availability bias) and current adherence rate (social norm).Results: Caregivers in Intervention 1 had a significantly higher adherence rate than Control (97.3% versus 90.9%) (p = 0.014). Both interventions had a significant effect on participants in their first prophylaxis season (p = 0.031, p = 0.037). Families where the father was employed had a 14.2% higher adherence rate (p = 0.001). Every additional child was associated with a 2.2% decrease in adherence rate (p = 0.02). In control, ICU admission history was associated with an 18.8% lower adherence rate (p = 0.0001), but this association disappeared in intervention groups.Conclusion: This is the first prospective interventional study which, in the context of palivizumab prophylaxis, analyses the effectiveness of nudge interventions based on established cognitive biases by comparing randomly generated intervention and control groups. We found that default bias and implementation intention have significant effects on adherence.Clinical trial, in the name and number “Adherence of palivizumab prophylaxis, NCT05778240” registered retrospectively. https://clinicaltrials.gov/ct2/show/NCT05778240.


  • Open Access

    Transverse arch stenting and its effect on systemic hypertension

    by İbRahim Halil Demir, Murat Kardas, İlKer Kemal Yucel, Rukiye İrEm Yekeler, Mustafa Orhan Bulut, Emine Hekim Yılmaz, Murat Sürücü, Serdar Epçaçan, Ahmet Celebi

    Background: This study aimed to investigate the safety and efficacy of transverse aortic arch stenting and evaluate the course of hypertension and the act of arch stenting on systemic hypertension. Methods: The transverse aortic arch stenting procedures between January 2007 and May 2023 were retrospectively analyzed. Detailed procedure information, technical aspects, pressure measurements, angiographic data, balloons and stents used, complications, and immediate results were examined. Early and mid-term results were assessed. Results: Eighteen patients (10 males and 8 females; mean age: 14.5±5.3 years; range, 4 to 23 years) were included in the study, all of whom were hypertensive before the procedure. The mean weight was 56.8±19.6 kg. In seven patients, the stent struts had to be dilated due to the stent causing jailing at the entrance of nearby arch vessels. After stenting, there was a significant increase in arch diameter and a decrease in ascending aorta pressure and the pressure gradient across the aorta. There were no early mortality or major complications. Late migration of the stent was observed in one patient. Three patients became normotensive immediately after the intervention, and five became drug-free during the follow-up. The requirement for dual antihypertensive therapy was significantly reduced. Conclusion: Residual transverse arch lesions may contribute to the persistence of systemic hypertension after coarctation treatment. Transverse arch stent implantation can be performed safely with favorable outcomes, facilitating better blood pressure control. However, it should be noted that these patients remain at risk for lifelong hypertension and should be closely monitored in this regard.

  • Open Access

    Comorbidity of behavioral problems and parental acceptance-rejection in children diagnosed with chest discomfort, palpitations, vasovagal syncope, and underlying heart disease: a multiple case-control study

    by Yasemin Nuran Dönmez, Dilek Giray, Serdar Epcacan, Siddika Songül Yalçin

    Background: Children who experience chest discomfort, palpitations, vasovagal syncope, and underlying heart disease often present a complex clinical picture. Not only are they dealing with potential cardiac issues, but they may also exhibit behavioral problems that can complicate the diagnostic and treatment process. Moreover, parental acceptance or rejection can significantly influence the child’s well-being and medical outcomes in such cases. This study aims to explore the comorbidity of behavioral problems and parental acceptance-rejection in children diagnosed with these cardiac symptoms and underlying heart disease. Methods: In a case-control study, the Parental Acceptance - Rejection Questionnaire and Parental version of Strengths and Difficulties Questionnaire (SDQ) was filled by parents of 314 patients from pediatric cardiology clinic. Results: The control group scored substantially lower overall according to SDQ. The vasovagal syncope subgroup was found to have considerably lower scores on the subscale. The group with chest discomfort scored highly in hostility and aggression in the PARQ. In comparison to the other groups, the vasovagal syncope and chest pain group demonstrated higher scores in undifferentiated rejection and total score. Conclusion: This study showed a correlation between children’s behavioral and emotional problems and cardiac symptoms. This states that children’s relationship with their parents has an impact on their symptoms. It will be necessary to conduct further studies to determine a causal association and devise preventative measures.


  • Cross or Not to Cross-Dilemma of the Pulmonary Arteries

    by Derya Bako, Yasemin Nuran Dönmez, Ulaş Yalım Uncu, Ezgi Yangın Ergon, Sinan Genç, Zerrin Karakuş Epçaçan, Şafak Alpat, Serdar Epçaçan

    We aimed to assess the frequency of criss-cross pulmonary arteries and associated intracardiac and vascular anomalies in patients who underwent CT angiography due to suspected congenital heart disease or vascular anomaly at our hospital. We retrospectively evaluated the CT angiography images of 355 patients aged 0–18 years between April 2018 and December 2022. The presence of the criss-cross pulmonary artery anomaly was assessed. Additionally, in patients with a criss-cross pulmonary artery anomaly, accompanying branch pulmonary artery anomalies, aortic arch anomalies, and other vascular-cardiac anomalies were also evaluated. A total of 331 patients’ images were evaluated. Criss-cross pulmonary artery anomaly was present in 57 patients (17.2%). Pulmonary artery branch anomaly was present in 16, aortic arch anomaly in 40 patients (70%) with criss-cross pulmonary artery anomaly, while associated intracardiac pathology (by echocardiography) was detected in 43 patients (75.4%). The frequency of criss-cross pulmonary artery was found to be significantly higher in patients with any aortic arch anomaly (p = 0.01). This study represents one of the largest series of patients with criss-cross pulmonary artery anomalies. Our results suggests that it may be more common than previously recognized and potentially overlooked. It is crucial to consider the presence of this anomaly in patients with complex aortic arch anomalies or cardiac pathologies, as it may have implications for surgical approaches and potential complications. Increased awareness of this anomaly among cardiologists and radiologists is necessary for accurate diagnosis and appropriate management.

  • Effects of levetiracetam treatment on autonomic nervous system functions in pediatric epilepsy patients

    by Meltem Çobanoğulları Direk, Serdar Epcacan, Asena Ayca Özdemir, Fahrettin Uysal, Çetin Okuyaz

    Background: This study investigated the effects of levetiracetam (LEV) treatment on cardiac rhythm and heart rate variability.Methods: The study included two groups of patients diagnosed with non‐lesional epilepsy who had not yet been treated and who presented to the outpatient pediatric neurology clinic at Van Training and Research Hospital, Van, Turkey, between 2019 and 2020. The heart rate variability (HRV) of 47 patients in the first group, before and at the 3rd month of treatment, and intravenous (IV) LEV loading in 13 patients in the second group was evaluated by Holter electrocardiography (ECG).Results: It was determined that the values of triangular index, standard deviation of the RR intervals over a 24‐hour period (SDNN), standard deviation of all 5‐minute mean RR intervals (SDANN), mean of standard deviations of all normal RR intervals (SDNNI), the percentage of RR intervals with >50‐millisecond variation (PNN50), and the square root of mean squared differences of successive RR intervals (RMSSD). HRV of 47 patients under LEV treatment significantly increased in the 3rd month of treatment compared to baseline (p < 0.05). No difference was found in HRV between the intravenous loading and the control group (p > 0.05).Conclusions: Our study suggests that the sympathovagal balance before treatment in the patient group is in favor of the sympathetic nervous system and that the sympathovagal imbalance improves after treatment. Our results show that LEV monotherapy and loading have no negative effect on HRV and potential cardiac arrhythmia risk in children with epilepsy.


  • Open Access

    Increased serum concentrations of growth differentiation factor-15 in children with acute rheumatic fever

    by Zerrin Karakuş-Epçaçan, Mehmet Gökhan Ramoğlu, Serdar Epçaçan

    Aim: In this single-centre prospective study, we aimed to evaluate the role of growth differentiation factor-15 in children with acute rheumatic fever.Methods: The study group included 25 children with acute rheumatic fever, and the control group included 25 healthy children. In addition to routine laboratory tests used in the diagnosis and treatment of acute rheumatic fever, growth differentiation factor-15 levels of the study group (at the time of diagnosis and after the treatment) and the control group were assessed and compared.Results: The mean growth differentiation factor-15 level of the study group at the time of diagnosis (918.40 ± 605.65 pg/ml) was significantly higher than the mean post-treatment level (653.08 ± 330.92 pg/ml) (p = 0.015). Similarly, the mean growth differentiation factor-15 level of the study group at the time of diagnosis was significantly higher than the control group (p = 0.04). However, mean growth differentiation factor-15 levels were similar between the groups after the treatment. Growth differentiation factor-15 was positively correlated with both C-reactive protein (p < 0.001) and erythrocyte sedimentation rate (p = 0.001) at the time of diagnosis.Conclusion: Growth differentiation factor-15 levels are significantly increased in children with acute rheumatic fever at the time of diagnosis and return to similar levels with healthy children after treatment. Growth differentiation factor-15 is positively and significantly correlated with erythrocyte sedimentation rate and C-reactive protein at the time of diagnosis.


  • Congenital biventricular cardiac diverticula as a part of class III Cantrell’s syndrome: case report

    by Derya Bako, Serdar Epçaçan, Dilek Giray, Zerrin Karakuş Epçaçan

    Congenital cardiac ventricular diverticulum is an extremely rare condition that usually occurs as a part of Pentalogy of Cantrell and frequently associated with sternal, pericardial, diaphragmatic, and thoracoabdominal wall defects. The prognosis of the patient depends on the complexity of abnormalities. Herein, we report biventricular diverticula as a part of incomplete Cantrell’s syndrome in a 1-day-old newborn.


  • A rare cause of hydrops fetalis in two Gaucher disease type 2 patients with a novel mutation

    by Sebile Kılavuz, Murat Basaranoglu, Serdar Epcacan, Derya Bako, Arife Ozer, Yasemin Nuran Donmez, Emine Ipek Ceylan, Ajlan Tukun, Serdar Ceylaner, Hadi Geylani, et al.

    Gaucher disease type 2 is the most progressive and the rarest form of Gaucher disease, defined as the acute neuronopathic type. We presented two GD2 patients who died before three months of age due to severe septicemia, respiratory and liver failure. One was homozygous for a novel GBA variant c.590 T > A (p.197 K), and the second homozygous for the known GBA mutation c.1505G > A (p.R502H). Ichthyosis, hydrops fetalis, apnea, myoclonic seizures, and hepatosplenomegaly occurred in both patients, but hypertrophic cardiomyopathy was observed only in the second and unilateral cataract in the first patient. Due to the disease’s early and rapid neurological progression, we did not administer ERT to our patients. It is strongly believed that early diagnosis is essential, and prenatal diagnosis makes genetic counselling possible for future pregnancies.


  • Acute myocarditis following COVID-19 mRNA vaccination: a paediatric case

    by Dilek Giray, Serdar Epçaçan

    Myocarditis is an inflammation of the heart muscle. In this case, a previously healthy, 17-year-old adolescent with myocarditis after BNT162b2 mRNA vaccination was reported. He was admitted to the hospital with severe chest pain, changes in electrocardiography, and elevation in serum troponin level after fourth day of receiving first dose of vaccine. There was no coronary arterial disease in coronary angiogram. A diagnosis of vaccine-induced myocarditis was made, and supportive treatment was initiated.